e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Treatment of IPF
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Minoru Inomata (Tokyo, Japan), Minoru Inomata, Yukiko Miura, Nariaki Kokuho, Hiroki Hayashi, Takahito Nei, Koichiro Kamio, Kazue Fujita, Yoshinobu Saito, Akihiko Gemma, Takefumi Saito, Arata Azuma
Source:
International Congress 2015 – Treatment of IPF
Session:
Treatment of IPF
Session type:
Oral Presentation
Number:
4497
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Minoru Inomata (Tokyo, Japan), Minoru Inomata, Yukiko Miura, Nariaki Kokuho, Hiroki Hayashi, Takahito Nei, Koichiro Kamio, Kazue Fujita, Yoshinobu Saito, Akihiko Gemma, Takefumi Saito, Arata Azuma. Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia. Eur Respir J 2015; 46: Suppl. 59, 4497
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016
Interstitial lung disease
Source: Eur Respir Rev 2013; 22: 26-32
Year: 2013
Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Variation in mortality from interstitial lung disease by diagnosis
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Significance of connective tissue disease features in idiopathic interstitial pneumonia
Source: Eur Respir J 2012; 39: 661-668
Year: 2012
Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Rituximab in severe, treatment-refractory interstitial lung disease
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Significance of histopathologic features suggesting connective tissue disease in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Aquoaporin-1 expression in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Study of factors affecting mortality in ILD cases over 2 years
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
ILD-India registry: Idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD) associated interstitial lung disease (CTD-ILD)
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Clinical features of microscopic polyangiitis with usual interstitial pneumonia-like fibrosis in comparison with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Using the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Rituximab in severe, progressive interstitial lung disease
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Idiopathic non-specific interstitial pneumonia (iNSIP): do the patients develop connective tissue disease (CTD) during follow-up?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept